Inventor · disambiguated record
Ronald Levy
Also filed as: LEVY RONALD
17 granted patents·17 pending applications·346 citations·filing 1983–2024
94Inventor score
Files withUNIV LELAND STANFORD JUNIOR19LEVY RONALD3ALIZADEH ARASH ASH2SWARTZ JAMES ROBERT2AULT-RICHE DANA1
Top patents by PatentIndex Score
34 records- 0193US9758589B2Methods for enhancing anti-tumor antibody therapyUNIV LELAND STANFORD JUNIOR·Filed 2014·Granted Sep 12, 2017·25 cites·36 claims
- 0291US7332280B2Classification of patients having diffuse large B-cell lymphoma based upon gene expressionLEVY RONALD·Filed 2004·Granted Feb 19, 2008·88 cites·11 claims
- 0390US9005619B2Methods for enhancing anti-tumor antibody therapyKOHRT HOLBROOK·Filed 2010·Granted Apr 14, 2015·39 cites·37 claims
- 0488US10633450B2Methods for enhancing anti-tumor antibody therapyUNIV LELAND STANFORD JUNIOR·Filed 2017·Granted Apr 28, 2020·3 cites·17 claims
- 0585US4661586AMonoclonal anti-idiotype antibodiesUNIV LELAND STANFORD JUNIOR·Filed 1983·Granted Apr 28, 1987·57 cites·7 claims
- 0682US8481045B2Immunogenic protein constructsSWARTZ JAMES ROBERT·Filed 2010·Granted Jul 9, 2013·6 cites·8 claims
- 0778US5512435AReceptor-binding antiproliferative peptidesFiled 1993·Granted Apr 30, 1996·51 cites·9 claims
- 0870US10040862B2Humanized and chimeric monoclonal antibodies to CD99UNIV LELAND STANFORD JUNIOR·Filed 2015·Granted Aug 7, 2018·1 cites·11 claims
- 0970US9109255B2Methods and compositions for determining responsiveness to antibody therapyLEVY RONALD·Filed 2005·Granted Aug 18, 2015·1 cites·12 claims
- 1067US4816249AMonoclonal anti-idiotype antibodiesUNIV LELAND STANFORD JUNIOR·Filed 1987·Granted Mar 28, 1989·35 cites·4 claims
- 1167US2025177559A1Branched lipid charge-altering releasable transporters for nucleic acid deliveryUNIV LELAND STANFORD JUNIOR·Filed 2023·Application pending·0 cites
- 1266US2024277854A1Immolative cell-penetrating complexes for nucleic acid delivery to the lungUNIV LELAND STANFORD JUNIOR·Filed 2024·Application pending·0 cites
- 1366US2024277870A1Immolative cell-penetrating complexes for nucleic acid deliveryUNIV LELAND STANFORD JUNIOR·Filed 2024·Application pending·0 cites
- 1464US2025381276A1Small molecule conjugated charge-altering releasable transporters for nucleic acid deliveryUNIV LELAND STANFORD JUNIOR·Filed 2023·Application pending·0 cites
- 1563US4513088AAssay for monoclonal antibody against surface Ig of a human B cell tumorUNIV LELAND STANFORD JUNIOR·Filed 1983·Granted Apr 23, 1985·22 cites·10 claims
- 1662US7622253B2Classification of patients having diffuse large b-cell lymphoma based upon gene expressionLEVY RONALD·Filed 2006·Granted Nov 24, 2009·1 cites·9 claims
- 1760US2020017915A1Methods and compositions for determining responsiveness to antibody therapyUNIV LELAND STANFORD JUNIOR·Filed 2019·Application pending·0 cites
- 1858US2010143926A1Classification of Patients Having Diffuse Large B-cell Lymphoma Based upon Gene ExpressionLIFE TECHNOLOGIES CORP·Filed 2009·Application pending·0 cites
- 1957US6099846AEnhancement of B cell lymphoma and tumor resistance using idiotype/cytokine conjugatesUNIV LELAND STANFORD JUNIOR·Filed 1993·Granted Aug 8, 2000·17 cites·7 claims
- 2055US2020397895A1Treatment using bruton's tyrosine kinase inhibitors and immunotherapyPHARMACYCLICS LLC·Filed 2020·Application pending·0 cites
- 2154US12215341B2Hybrid immolative cell-penetrating complexes for nucleic acid deliveryUNIV LELAND STANFORD JUNIOR·Filed 2019·Granted Feb 4, 2025·0 cites·15 claims
- 2254US2022257785A1Knottin-immunostimulant conjugates and related compositions and methodsUNIV LELAND STANFORD JUNIOR·Filed 2020·Application pending·0 cites
- 2352US11931416B2Immolative cell-penetrating complexes for nucleic acid delivery to the lungUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Mar 19, 2024·0 cites·13 claims
- 2452US2016235842A1Medical uses of cd38 agonistsUNIV LELAND STANFORD JUNIOR·Filed 2014·Application pending·0 cites
- 2552US2024148858A1A three component vaccine for covid-19UNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 2651US2004101522A1Transduced neoplastic cell preparations able to express T-cell costimulatory molecules B7.1, ICAM-1, and LFA-3 and induce immunostimulatory prophylactic and therapeutic anti-tumor effects in-vivoTHERION BIOLOG CORP·Filed 2003·Application pending·0 cites
- 2750US2011129438A1Immunogenic protein constructsSWARTZ JAMES ROBERT·Filed 2007·Application pending·0 cites
- 2850US2015118222A1Treatment using bruton's tyrosine kinase inhibitors and immunotherapyPHARMACYCLICS INC·Filed 2014·Application pending·0 cites
- 2947US2015315660A1Methods and compositions for determining responsiveness to antibody therapyUNIV LELAND STANFORD JUNIOR·Filed 2015·Application pending·0 cites
- 3045US2003219818A1Methods and compositions for determining neoplastic disease responsiveness to antibody therapyFiled 2003·Application pending·0 cites
- 3144US2006018911A1Design of therapeutics and therapeuticsAULT-RICHE DANA·Filed 2005·Application pending·0 cites
- 3243US9605320B2Method of predicting responsiveness of B cell lineage malignancies to active immunotherapyALIZADEH ARASH ASH·Filed 2012·Granted Mar 28, 2017·0 cites·4 claims
- 3337US10815306B2Humanized and chimeric monoclonal antibodies to CD81UNIV LELAND STANFORD JUNIOR·Filed 2017·Granted Oct 27, 2020·0 cites·11 claims
- 3431US2012134986A1Methods of Prognosis for Non-Hodgkin LymphomaALIZADEH ARASH ASH·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ronald Levy files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →